(EMAILWIRE.COM, January 30, 2018 ) Browse 110 market data Tables and 37 Figures spread through 223 Pages and in-depth TOC on "Esoteric Testing Market"
https://www.marketsandmarkets.com/Market-Reports/esoteric-testing-market-76794708.html
Early buyers will receive 10% customization on this report.

Factors such as increasing burden of chronic diseases (majorly due to the rising geriatric population), rising prevalence of infectious diseases, rising demand for early disease diagnosis using specialized tests, growing awareness on personalized medicine, and increasing government funding for the research and development of innovative esoteric tests are driving the market growth.

Moreover, the introduction of a new range of condition-specific markers and tests, with advances in genomics and proteomics, is expected to offer significant growth opportunities for market players during the forecast period.

Based on type, the infectious diseases testing segment is expected to dominate the market during the forecast period.

Based on type, the esoteric testing market is broadly divided into infectious diseases, immunology, endocrinology, oncology, genetics, toxicology, neurology, and others (hematological tests, coagulation tests, nephrology tests, cardiovascular test panels, occupational tests, and donor and forensic). The infectious diseases testing segment is expected to grow at the highest CAGR during the forecast period.

This growth is primarily attributed to the large volume of infectious disease tests being performed in clinical laboratories, growing global disease burden of chronic and infectious disorders, technological innovations in molecular diagnostics, and improving healthcare infrastructure in developing nations.

Download the PDF Brochure@
https://www.marketsandmarkets.com/pdfdownload.asp?id=76794708

Based on technology, the chemiluminescence immunoassay (CLIA) segment is estimated to have the largest share of the market in 2018.

Based on technology, the esoteric testing market is broadly divided into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), mass spectrometry, flow cytometry, radioimmunoassay, real-time PCR (qPCR), and other technologies.

The CLIA segment is expected to dominate the market in 2018. The large share of this segment is attributed to the advantages of CLIA over other testing methods, including high-performance levels, low detection limits, higher specificity, high signal intensity, and good precision.

Based on laboratory type, independent and reference laboratories are expected to witness the highest growth during the forecast period.

Based on laboratory type, the market is segmented into independent & reference laboratories and hospital-based laboratories. The independent and reference laboratories segment is expected to register the highest CAGR during the forecast period.

The high growth of this segment is attributed to the ongoing automation and digitalization of diagnostic laboratories across major countries and significant reimbursement coverage for clinical tests performed at reference/independent laboratories in developed countries.

Get the Sample Pages@
https://www.marketsandmarkets.com/requestsample.asp?id=76794708

North America is expected to dominate the esoteric testing market in 2018.

Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America is expected to dominate the market followed by Europe. The market in North America is primarily driven by the accessibility to advanced technologies, the presence of a well-established network of independent clinical laboratories, expansion of molecular diagnostics for genetic disorders and cancer screening, and presence of major leading companies in the US.

The prominent players in the global esoteric testing market include LabCorp (US), OPKO Health (US), ARUP Laboratories (US), Miraca Holdings (Japan), Myriad Genetics (US), Genomic Health (US), Quest Diagnostics (US), American Medical Laboratories (US), Foundation Medicine (US), Mayo Medical Laboratories (US), Primary Healthcare (Australia), Healthscope (Australia), Sonic Healthcare (Australia), Fulgent Genetics. (US), Invitae (US), Spectra Laboratories (US), Eurofins Scientific (Luxembourg), Unilabs (Switzerland), SYNLAB International (Germany), Enzo Biochem (US), Clinical Reference Laboratory (US), Sequenom (US), and American Pathology Partners (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com